Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Status:	Completed
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	10/20/2017
Start Date:	March 3, 2011
End Date:	June 22, 2017

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects
with advanced or metastatic solid tumors who no longer respond to or have relapsed from
standard therapies.

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Subjects with advanced or metastatic solid tumors (non-hematologic refractory to or
relapsed from standard therapies or for which there is no known effective treatment
during dose escalation

- Subjects with squamous non-small cell lung cancer and triple-negative breast cancer or
other solid tumor types for which Notch activation has been demonstrated (such as
pancreatic, ovarian and melanoma) during dose expansion

- Biopsy accessible tumor (may be waived under certain circumstances)

- Life expectancy of at least 3 months

- Eastern Cooperative Oncology Group (ECOG) 0-1

- Adequate organ and bone marrow function

Exclusion Criteria:

- Infection

- Elevated triglycerides

- Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel
disease (IBD)]

- Taking medications known to increase risk of Torsades De Pointes

We found this trial at

sites

Winship Cancer Institute

Atlanta, Georgia 30322

from

Atlanta, GA